Skip to content

The significance of inferior vena cava cross-sectional area and circulating non-coding RNA in evaluating early volume resuscitation in septic shock.

Significance of ultrasound vascular monitoring and circulating non coding RNA in early volume resuscitation of septic shock

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040380
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-11-23
Completion date
Unknown
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Gold Standard:1.Clinical diagnostic criteria for sepsis: infection, with changes in SOFA score >=2 points. 2.Clinical diagnostic criteria for septic shock: on the basis of definite diagnosis of sepsis
ultrasound&#32
of&#32
area. molecular&#32
markers&#32
to&#32
resuscitation&#32
in&#32
patients

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. Critically ill patients diagnosed with septic shock and require PICCO to monitor hemodynamics. Septic shock was diagnosed according to the international guidelines for sepsis and septic shock in 2016; 3. There is enough time for bedside ultrasound monitoring, PICCO monitoring and exploration of capacity-related molecular biological markers.

Exclusion criteria

Exclusion criteria: 1. Patients with PICCO catheterization contrains, such as poor arterial conditions, arterial plaques, venous thrombosis, coagulation dysfunction, local infection in the puncture area, etc.; 2. Bedside ultrasound examination is difficult to obtain clear and stable images of patients, such as chest injury, deformity, inferior vena cava unclear display, etc.; 3. Patients with arrhythmia, such as atrial fibrillation, frequent contraction, etc.; 4. Patients with malignant tumors and intra-abdominal high pressure; 5. Patients with AIDS and severe infectious diseases; 6. Patients during lactation or pregnancy; 7. Patients with terminal malignancy; 8. Refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
ITBVI;GEDV;CO;Cross-sectional area of inferior vena cava, Rate of variation in inferior vena cava cross-sectional area;

Secondary

MeasureTime frame
IVCD;Variation rate of inferior vena cava diameter;LVEDV;LVEF;Jugular vein diameter;Variation rate of Jugular vein diameter;Organ Function Index (LDH, CK-MB, TNT; ALB, ALT, ALP, D-BIL, I-BIL, AST, AMY, BA, BUN, Cr; PT, INR, APTT, Fib, D-D, FDP; CRP, WBC, HB, PLT, N%, L%);Arterial blood gas analysis (PH, Lac);Volume index (NT-pro-BNP, HCT);Infected index(PCT);Vital sign (T, HR, RR, BP, MBP, SpO2, HRV);Volume index (CVP);Intake and output volume (Venous Access volume, Gastrointestinal decompression volume, Wound drainage, Fecal quantity, The amount of EN or TPN, The types of EN or TPN);Vasoactive drug (types, amount);CIS (APACHE II score (include GCS score), SOFA score, MODS score);Clinostatism (Renin, Angiotensin, ADS);

Countries

China

Contacts

Public ContactLiu Yongchao

Shanghai Tenth People's Hospital

lyc_mars123@163.com+86 18917681031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026